News
Public · Published
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. At Week 24, the drug reduced heterotopic ossification lesion volume and improved clinician-assessed joint mobility, with no treated patients developing new lesions.
Published:
Updated:
What happened
Mirum Pharmaceuticals announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. At Week 24, the drug reduced heterotopic ossification lesion volume and improved clinician-assessed joint mobility, with no treated patients developing new lesions.
Confirmed
Global impact / market context
Positive results in younger children could support a supplemental New Drug Application in the first half of 2027, potentially widening the patient group that can receive ATEBRIOZ. That expansion could raise future revenue for Mirum, spread fixed costs over more patients, and strengthen its position in rare bone disease treatments.
Analyst inference
ATEBRIOZ already has U.S. Food and Drug Administration approval for patients aged 12 and older, so this readout extends an existing franchise rather than launching a new one. Investors may weigh the added pediatric opportunity against the cost and timing risk of the planned regulatory submission.
Analyst inference
What to watch
- Mirum plans to submit a supplemental New Drug Application in the first half of 2027 to expand the ATEBRIOZ indication to children aged 6 to under 12 years. Confirmed
- The company intends to discuss the Cohort 2 findings with the U.S. Food and Drug Administration to seek expanded access for younger children. Proposed
- Watch whether regulators accept the Week 24 lesion-volume and joint-mobility data as sufficient support for approval in this younger age group. Analyst inference
Evidence
- Original source link unavailable